TY - JOUR
T1 - Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease
AU - Zeng, Cong
AU - Guo, Chunyuan
AU - Cai, Juan
AU - Tang, Chengyuan
AU - Dong, Zheng
N1 - Funding Information:
This study was supported in part by grants from the National Natural Science Foundation of China (81528004 and 81430017), the National Institutes of Health (DK058831, DK087843) and Department of Veterans Affairs of USA (BX000319).
Publisher Copyright:
© 2017, © The Author(s) 2017.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.
AB - Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.
KW - Chronic kidney disease
KW - Wnt
KW - sclerostin
KW - vascular calcification
UR - http://www.scopus.com/inward/record.url?scp=85042286971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042286971&partnerID=8YFLogxK
U2 - 10.1177/1479164117742316
DO - 10.1177/1479164117742316
M3 - Review article
C2 - 29168393
AN - SCOPUS:85042286971
SN - 1479-1641
VL - 15
SP - 99
EP - 105
JO - Diabetes and Vascular Disease Research
JF - Diabetes and Vascular Disease Research
IS - 2
ER -